<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 45-year-old woman with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome (APS) and <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> was admitted because of severe <z:hpo ids='HP_0002094'>dyspnea</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>She had undergone mitral valve replacement (MVR) using a Mosaic bioprosthesis for infective <z:hpo ids='HP_0100584'>endocarditis</z:hpo> 9 years previously </plain></SENT>
<SENT sid="2" pm="."><plain>She developed <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> secondary to mitral bioprosthetic valve stenosis resulting from relatively early structural valve deterioration </plain></SENT>
<SENT sid="3" pm="."><plain>She underwent a second MVR using a mechanical valve prosthesis </plain></SENT>
<SENT sid="4" pm="."><plain>The explanted bioprosthesis showed marked <z:e sem="disease" ids="C0155094,C0333350" disease_type="Disease or Syndrome;Finding" abbrv="">pannus</z:e> formation and mineralization with fibrin <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation, especially on the outflow surfaces of the leaflets </plain></SENT>
<SENT sid="5" pm="."><plain>After the second operation, she was discharged without APS-related <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> under meticulous <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and antiplatelet therapies </plain></SENT>
</text></document>